purely because he's one in a million
Manny has congenital factor XIII deficiency; Michigan, USA
The only recombinant therapy for
congenital factor XIII A-subunit deficiency
Tretten® helps prevent bleeds in people with congenital factor XIII A-subunit deficiency.
Learn more about starting your journey with Tretten® using these resources available from Novo Nordisk.
Patient assistance programs
Start treatment with TrettenSTART™
With TrettenSTART™, people prescribed Tretten® for congenital factor XIII A-subunit deficiency can begin their treatment with 2 FREE doses (2 months) of Tretten®.
To be eligible, individuals must have undergone testing indicating that they have factor XIII A-subunit deficiency. Completion of both the Physician Form and Patient Form is also required for enrollment in the program. Enrollees will then be mailed their free trial prescription along with a Starter Kit with information about Tretten®.Download physician form Download patient form
For more information about TrettenSTART™,
please call 1-844-Tretten (1-844-873-8836).
Vanessa has congenital factor XIII deficiency; Ohio, USA
Get help when it’s needed with TrettenASSIST™
A rare bleeding disorder diagnosis such as congenital factor XIII A-subunit deficiency can bring up a host of insurance issues. But TrettenASSIST™ may be able to help. Individuals with congenital factor XIII A-subunit deficiency may be eligible to receive up to 3 free doses of Tretten® if they:
- Are currently uninsured
- Have no options for alternate coverage
- Have a gap in coverage
Please call toll-free 1-844-Tretten (1-844-873-8836)
for more information about TrettenASSIST™.
HCP resources for ordering Tretten®
Click here if you are a healthcare provider (HCP) interested in ordering Tretten®. This information is intended for use only by HCPs in the United States.
Important Safety Information
Who should not use Tretten®?
- You should not use Tretten® if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reaction (anaphylaxis) to Tretten® or any of the ingredients.
What should I tell my healthcare provider before Tretten® is given?
- Tell your healthcare provider about all of your medical conditions, including if you are pregnant, think you may be pregnant or planning to become pregnant, are breast feeding, or have a history of blood clots.
- Tell your healthcare provider and pharmacist about all of the medicines you take, including all prescription and non-prescription medicines such as over-the-counter medicines, supplements, or herbal remedies.
What are the possible side effects of Tretten®?
- Call your healthcare provider or go to the emergency department right away if you have any of the following symptoms after using Tretten®:
- Signs of allergic reaction, including shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness.
- Signs of a blood clot including pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, or sudden severe headache and/or loss of consciousness or function.
- Unexpected bleeding.
- Other possible side effects may include pain in your arms or legs, headache, and pain at the injection site.
- These are not all the possible side effects of Tretten®. Tell your healthcare provider about any side effect that bothers you or that does not go away.
Indications and Usage
What is Tretten® (Coagulation Factor XIII A-Subunit [Recombinant])?
- Tretten® is an injectable medicine used to prevent bleeding in adults and children who have congenital Factor XIII (FXIII) A-subunit deficiency.
- Tretten® is not for use in patients with congenital Factor XIII B-subunit deficiency.
Please click here for Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Tretten® is a prescription medicine. Novo Nordisk provides patient assistance for those who qualify. Please call 1-844-Tretten (1-844-873-8836) to learn more about Novo Nordisk assistance programs.